Payload Information
General Information of This Payload
| Payload ID | PAY0DZNQW |
|||||
|---|---|---|---|---|---|---|
| Name | N10-beta-glucuronide SG3200 |
|||||
| Synonyms |
N10-beta-glucuronide SG3200
Click to Show/Hide
|
|||||
| Target(s) | Human Deoxyribonucleic acid (hDNA) | |||||
| Structure |
|
|||||
| Formula | C45H49N5O19 |
|||||
| Isosmiles | C=C1CC2C(O)Nc3cc(OCCCOc4cc5c(cc4OC)C(=O)N4CC(=C)CC4C(O)N5C(=O)OCc4ccc(OC5OC(C(=O)O)C(O)C(O)C5O)c([N+](=O)[O-])c4)c(OC)cc3C(=O)N2C1 |
|||||
| InChI |
InChI=1S/C45H49N5O19/c1-20-10-28-39(54)46-25-15-33(31(63-3)13-23(25)40(55)47(28)17-20)65-8-5-9-66-34-16-26-24(14-32(34)64-4)41(56)48-18-21(2)11-29(48)42(57)49(26)45(60)67-19-22-6-7-30(27(12-22)50(61)62)68-44-37(53)35(51)36(52)38(69-44)43(58)59/h6-7,12-16,28-29,35-39,42,44,46,51-54,57H,1-2,5,8-11,17-19H2,3-4H3,(H,58,59)
|
|||||
| InChIKey |
ALWNMTLERNTSNF-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
963.903 |
Polar area |
319.16 |
||
Complexity |
69 |
xlogp Value |
1.4914 |
|||
Heavy Count |
69 |
Rot Bonds |
14 |
|||
Hbond acc |
19 |
Hbond Donor |
7 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Half Maximal Inhibitory Concentration (IC50) | 1080.0±30.5 | nM |
MDA-MB-361 cells
|
Breast adenocarcinoma
|
[1] | |
| Half Maximal Inhibitory Concentration (IC50) | 1812.7±62.0 | nM |
MCF-7 cells
|
Invasive breast carcinoma
|
[1] | |
| Half Maximal Inhibitory Concentration (IC50) | >2000 | nM |
JIMT-1 cells
|
Breast ductal carcinoma
|
[1] | |
| Half Maximal Inhibitory Concentration (IC50) | 2702.3±998.3 | nM |
NCI-N87 cells
|
Gastric tubular adenocarcinoma
|
[1] | |
| Half Maximal Inhibitory Concentration (IC50) | 2949.0±562.0 | nM |
SK-OV-3 cells
|
Ovarian serous cystadenocarcinoma
|
[1] |
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
Trastuzumab-C239I-SG3600 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 62.20% (Day 50) | Low HER2 expression (HER2+) | ||
| Method Description |
The antitumor activity of trastuzumab-C239i-SG3600 was evaluated in the low-HER2-expressing,trastuzumab-resistant human breast cancer model JIMT-1 and the HER2-positive human gastric cancer xenograft model NCI-N87. A sub-curative single dose of ADC of 1 mg/kg was chosen for both ADCs to observe any difference in activity.
|
||||
| In Vivo Model | Gastric cancer CDX model | ||||
| In Vitro Model | Gastric cancer | Gastric cancer cells | Homo sapiens | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 65.10% (Day 50) | Negative expression (HER2-) | ||
| Method Description |
The antitumor activity of trastuzumab-C239i-SG3600 was evaluated in the low-HER2-expressing,trastuzumab-resistant human breast cancer model JIMT-1 and the HER2-positive human gastric cancer xenograft model NCI-N87. A sub-curative single dose of ADC of 1 mg/kg was chosen for both ADCs to observe any difference in activity.
|
||||
| In Vivo Model | Breast cancer CDX model | ||||
| In Vitro Model | Breast cancer | Breast cancer cells | Homo sapiens | ||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 100.00% (Day 50) | Low HER2 expression (HER2+) | ||
| Method Description |
The antitumor activity of trastuzumab-C239i-SG3600 was evaluated in the low-HER2-expressing,trastuzumab-resistant human breast cancer model JIMT-1 and the HER2-positive human gastric cancer xenograft model NCI-N87. A sub-curative single dose of ADC of 3 mg/kg was chosen for both ADCs to observe any difference in activity.
|
||||
| In Vivo Model | Gastric cancer CDX model | ||||
| In Vitro Model | Gastric cancer | Gastric cancer cells | Homo sapiens | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
16.10 ng/mL
|
Low HER2 expression (HER2+) | ||
| Method Description |
The cytotoxicity of the HER2-targeting ADCs was examined in vitro. Every cell line after treatment for 144h with doses ranging from 0.01 to 10, 000 ng/mL. Results are meanSEM of three replicate experiments.
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
24.10 ng/mL
|
Low HER2 expression (HER2+) | ||
| Method Description |
The cytotoxicity of the HER2-targeting ADCs was examined in vitro. Every cell line after treatment for 144h with doses ranging from 0.01 to 10, 000 ng/mL. Results are meanSEM of three replicate experiments.
|
||||
| In Vitro Model | Ovarian serous cystadenocarcinoma | SK-OV-3 cells | CVCL_0532 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
33.90 ng/mL
|
Low HER2 expression (HER2+) | ||
| Method Description |
The cytotoxicity of the HER2-targeting ADCs was examined in vitro. Every cell line after treatment for 144h with doses ranging from 0.01 to 10, 000 ng/mL. Results are meanSEM of three replicate experiments.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 10.00 ug/mL | Negative expression (HER2-) | ||
| Method Description |
The cytotoxicity of the HER2-targeting ADCs was examined in vitro. Every cell line after treatment for 144h with doses ranging from 0.01 to 10, 000 ng/mL. Results are meanSEM of three replicate experiments.
|
||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 10.00 ug/mL | Negative expression (HER2-) | ||
| Method Description |
The cytotoxicity of the HER2-targeting ADCs was examined in vitro. Every cell line after treatment for 144h with doses ranging from 0.01 to 10, 000 ng/mL. Results are meanSEM of three replicate experiments.
|
||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
Trastuzumab-SG3600 high DAR [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
3.60 ng/mL
|
Low HER2 expression (HER2+) | ||
| Method Description |
The cytotoxicity of the HER2-targeting ADCs was examined in vitro. Every cell line after treatment for 144h with doses ranging from 0.01 to 10, 000 ng/mL. Results are meanSEM of three replicate experiments.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-231 cells | CVCL_0062 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
5.37 ng/mL
|
Low HER2 expression (HER2+) | ||
| Method Description |
The cytotoxicity of the HER2-targeting ADCs was examined in vitro. Every cell line after treatment for 144h with doses ranging from 0.01 to 10, 000 ng/mL. Results are meanSEM of three replicate experiments.
|
||||
| In Vitro Model | Ovarian serous cystadenocarcinoma | SK-OV-3 cells | CVCL_0532 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
5.90 ng/mL
|
Low HER2 expression (HER2+) | ||
| Method Description |
The cytotoxicity of the HER2-targeting ADCs was examined in vitro. Every cell line after treatment for 144h with doses ranging from 0.01 to 10, 000 ng/mL. Results are meanSEM of three replicate experiments.
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
36.10 ng/mL
|
Negative expression (HER2-) | ||
| Method Description |
The cytotoxicity of the HER2-targeting ADCs was examined in vitro. Every cell line after treatment for 144h with doses ranging from 0.01 to 10, 000 ng/mL. Results are meanSEM of three replicate experiments.
|
||||
| In Vitro Model | Breast ductal carcinoma | JIMT-1 cells | CVCL_2077 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 10.00 ug/mL | Negative expression (HER2-) | ||
| Method Description |
The cytotoxicity of the HER2-targeting ADCs was examined in vitro. Every cell line after treatment for 144h with doses ranging from 0.01 to 10, 000 ng/mL. Results are meanSEM of three replicate experiments.
|
||||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cells | CVCL_0031 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.